Systematic review and meta-analysis demonstrates superior laryngeal nerve block improves cough severity in chronic cough, highlighting its potential as a targeted refractory treatment option.
Background and Objectives: To evaluate the efficacy of superior laryngeal nerve block (SLB) in the management of chronic cough associated with refractory laryngeal hypersensitivity. Materials and Methods: Studies assessing Cough Severity Index (CSI) changes before and after SLB or comparing SLB with sham interventions were included. Pooled analyses evaluated CSI reduction, subjective improvement, and adverse events. Results: Twelve studies involving 759 patients were analyzed. SLB significantly reduced CSI, and the improvement was maintained within the available follow-up period, with no difference between short-term (<100 days) and long-term (>100 days) follow-up (p = 0.5145). Most protocols used initial unilateral SLB with contralateral injection for non-responders, resulting in more than two blocks per patient on average. Subjective improvement occurred in 74%, with ≥50% CSI reduction in 55% and satisfactory response after a single block in 17%. No serious treatment-related adverse events were reported, although the available evidence was insufficient to exclude rare or delayed complications. Conclusions: SLB was associated with improvement in refractory chronic cough in predominantly uncontrolled observational studies. Although one small placebo-controlled trial suggested benefit over saline injection, the current evidence remains insufficient to establish definitive efficacy, and adequately powered placebo-controlled randomized controlled trials are needed to confirm its efficacy and durability.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: